• HOME
• ABOUT
  ACCC
  • Core Purpose, Values, & Objectives
  • Governance & Leadership
  • Elections
  • Awards
  • History
  • Annual Report
  • Corporate Partnerships
  • Staff
• MEMBERSHIP
  • Cancer Program Membership
  • Individual Membership
  • Chapter Membership
  • Update Your Member Info
• MEETINGS
  • Annual Meeting
  • National Oncology Conference
  • Oncology Reimbursement Meetings
  • Oncology State Society Meetings
  • Financial Advocacy Network Meetings
  • Oncology Pharmacy Meetings
  • ICLIO National Conference
  • Meetings Calendar
• PROVIDER
  RESOURCES
  • Cancer Types
  • Financial Advocacy Network
  • Immuno-Oncology
  • Molecular Testing
  • Pharmacy/Chemotherapy
  • Practice Improvement
  • Supportive Care
  • CME/CE Opportunities
• POLICY &
  ADVOCACY
  • Legislative Action Center
  • OCM Resource Center
  • Hospital Outpatient Issues
  • Physician Practice Issues
  • Coverage and Payment Issues
  • Healthcare Reform Law
  • Tips and Resources
• PUBLICATIONS
  • Oncology Issues Journal
    • Oncology Issues Supplements
    • Subscription/Ordering
  • Patient Assistance Guide
  • NCI NCCCP Monograph
  • Cancer Program Guidelines
  • Oncology Drug Database
  • ACCC Surveys
• CAREER
  CENTER
  • Browse Job Categories
  • Post a Job
  • Rate Information
  • Contact Us
• MEDIAROOM
  • Oncology Newsfeed
  • Press Releases
  • Advertising Opportunities
  • Privacy Policies
  • Whitelisting Information
•  

     

Search Drug Alphabetically

• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z

Generic Name	Binimetinib
Brand Name	Mektovi®
Payment Category	Medicare Part D
Year Introduced	2018
Type of Drug	Kinase inhibitor
Manufacturer	Array Biopharma
Medical Affairs Questions (date verified)	844.792.7729
Coverage & Reimbursement Questions	866.277.2927
FDA-Approved Indication(s) Indicated, in combination with ecorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. (1/19/19)
Approved Indication(s) with Orphan Drug Status	(In combination with encorafenib) Treatment of Stage III-IV melanoma positive for BRAF mutation
ICD-10 Code(s) for Labeled Indication(s)	Melanoma [C43.xx]

Name	Strength	Form	Package	Labeler	NDC

About the ACCC
Oncology Drug Database

Disclaimer &
Update Policy

ACCC's Patient Assistance
and Reimbursement Guide

ACCC Provider Resources

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US